From January 27 to January 28, 2024, the 19th China Honest Entrepreneurs Conference and the fifth China Brand Conference were held in Beijing Convention Center. China Honest Entrepreneurs Conference was founded in 2004, with the purpose of spreading entrepreneurship, promoting honest innovation models, and promoting the spirit of scientific and technological innovation, it is an important platform to focus on showing honest enterprises and entrepreneurs.
Weijin Biology was invited to attend this conference, and was unanimously elected by the Credit Work Committee of China Market Society, the Credit Evaluation Research Center of China Academy of Management Science, the Business School of China Academy of Management Science and other units, and awarded the company the honorary title of "AAA credit unit of China Market Credit" and "Advanced Unit of Credit Construction". To commend the outstanding contributions made by the company in the construction of corporate integrity. Mr. Chen Su, chairman of the company, was awarded the honorary title of "Outstanding Individual of Integrity Construction" in recognition of Mr. Chen Su's outstanding performance in enterprise integrity construction.
Weijin Biology was established in Chengdu on January 12, 2022, and has laid out nearly 5,000 square meters of office test integration sites in Chengdu and other places, with more than 200 project personnel directly involved in the company. At present, the company has completed the global clinical sample production of the core product pipeline, and is cooperating with the Clinical Center for Organ Transplantation of the University of Colorado, the Cancer Research Center of Ohio State University, the United States. Wuhan Institute of Virology, Chinese Academy of Sciences, Sichuan Provincial Institute of Drug Testing, Thomas Jefferson University Hematologic Oncology Center and other institutions have conducted close cooperation to jointly promote international multi-center clinical research on multiple indications of the company's product pipeline. At the same time, the company has gradually been recognized by the industry and investors, and won the honorary title of "China's Top 100 Pharmaceutical Innovation Value Discovery" from 2022 to 2023, with a cumulative financing amount of nearly 100 million yuan.
